ondansetron has been researched along with Cancer of Esophagus in 2 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess, in a prospective, observational study, the safety and efficacy of the addition of the neurokinin-1-receptor antagonist (NK1-RA) aprepitant to concomitant radiochemotherapy, for the prophylaxis of radiation therapy-induced nausea and vomiting." | 9.20 | Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. ( Jahn, F; Jahn, P; Jordan, K; Riesner, A; Sieker, F; Vordermark, D, 2015) |
| "To assess, in a prospective, observational study, the safety and efficacy of the addition of the neurokinin-1-receptor antagonist (NK1-RA) aprepitant to concomitant radiochemotherapy, for the prophylaxis of radiation therapy-induced nausea and vomiting." | 5.20 | Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. ( Jahn, F; Jahn, P; Jordan, K; Riesner, A; Sieker, F; Vordermark, D, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jahn, F | 1 |
| Riesner, A | 1 |
| Jahn, P | 1 |
| Sieker, F | 1 |
| Vordermark, D | 1 |
| Jordan, K | 1 |
| Miyashita, M | 1 |
| Onda, M | 1 |
| Ikeda, K | 1 |
| Bando, K | 1 |
| Hagiwara, N | 1 |
| Tsuchiya, Y | 1 |
| Yoshiyuki, T | 1 |
| Kiyama, T | 1 |
| Saito, T | 1 |
| Sasajima, K | 1 |
| Yamashita, K | 1 |
1 trial available for ondansetron and Cancer of Esophagus
| Article | Year |
|---|---|
Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Chemoradiotherapy; Cisplatin; Dexamethasone; Drug Th | 2015 |
1 other study available for ondansetron and Cancer of Esophagus
| Article | Year |
|---|---|
[Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1999 |